These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17476705)

  • 1. Tiagabine for social anxiety disorder.
    Dunlop BW; Papp L; Garlow SJ; Weiss PS; Knight BT; Ninan PT
    Hum Psychopharmacol; 2007 Jun; 22(4):241-4. PubMed ID: 17476705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label study of tiagabine in panic disorder.
    Sheehan DV; Sheehan KH; Raj BA; Janavs J
    Psychopharmacol Bull; 2007; 40(3):32-40. PubMed ID: 18007567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.
    Vaishnavi S; Alamy S; Zhang W; Connor KM; Davidson JR
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1464-9. PubMed ID: 17698275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study.
    Pollack MH; Roy-Byrne PP; Van Ameringen M; Snyder H; Brown C; Ondrasik J; Rickels K
    J Clin Psychiatry; 2005 Nov; 66(11):1401-8. PubMed ID: 16420077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
    Pollack MH; Tiller J; Xie F; Trivedi MH
    J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label tiagabine monotherapy for major depressive disorder with anxiety.
    Carpenter LL; Schecter JM; Tyrka AR; Mello AF; Mello MF; Haggarty R; Price LH
    J Clin Psychiatry; 2006 Jan; 67(1):66-71. PubMed ID: 16426090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.
    Rosenthal M
    J Clin Psychiatry; 2003 Oct; 64(10):1245-9. PubMed ID: 14658975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiagabine in anxiety disorders.
    Schwartz TL; Nihalani N
    Expert Opin Pharmacother; 2006 Oct; 7(14):1977-87. PubMed ID: 17020423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study of tiagabine as augmentation therapy for anxiety.
    Schwartz TL; Azhar N; Husain J; Nihalani N; Simionescu M; Coovert D; Jindal S; Tirmazi S
    Ann Clin Psychiatry; 2005; 17(3):167-72. PubMed ID: 16433059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose tiagabine effectiveness in anxiety disorders.
    Schaller JL; Thomas J; Rawlings D
    MedGenMed; 2004 Sep; 6(3):8. PubMed ID: 15520630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder.
    Davidson JR; Brady K; Mellman TA; Stein MB; Pollack MH
    J Clin Psychopharmacol; 2007 Feb; 27(1):85-8. PubMed ID: 17224720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder.
    Schwartz TL; Nasra GS; Ashton AK; Kang D; Kumaresan H; Chilton M; Bertone F
    Ann Clin Psychiatry; 2007; 19(1):25-30. PubMed ID: 17453658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects.
    Paparrigopoulos T; Tzavellas E; Karaiskos D; Malitas P; Liappas I
    J Psychopharmacol; 2010 Sep; 24(9):1375-80. PubMed ID: 19346278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability.
    Montgomery S; Emir B; Haswell H; Prieto R
    Curr Med Res Opin; 2013 Oct; 29(10):1223-30. PubMed ID: 23808960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment.
    Connor KM; Davidson JR; Weisler RH; Zhang W; Abraham K
    Psychopharmacology (Berl); 2006 Jan; 184(1):21-5. PubMed ID: 16341846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder.
    Zwanzger P; Eser D; Nothdurfter C; Baghai TC; Möller HJ; Padberg F; Rupprecht R
    Pharmacopsychiatry; 2009 Nov; 42(6):266-9. PubMed ID: 19924586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiagabine for posttraumatic stress disorder: a case series of 7 women.
    Taylor FB
    J Clin Psychiatry; 2003 Dec; 64(12):1421-5. PubMed ID: 14728102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study.
    Gonzalez G; Sevarino K; Sofuoglu M; Poling J; Oliveto A; Gonsai K; George TP; Kosten TR
    Addiction; 2003 Nov; 98(11):1625-32. PubMed ID: 14616189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
    Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
    Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder.
    Evans KC; Simon NM; Dougherty DD; Hoge EA; Worthington JJ; Chow C; Kaufman RE; Gold AL; Fischman AJ; Pollack MH; Rauch SL
    Neuropsychopharmacology; 2009 Jan; 34(2):390-8. PubMed ID: 18536708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.